Greenleaf Trust Decreased Gw Pharmaceuticals Plc Adr (GWPH) Holding; Harsco (HSC) Had 5 Analysts Last Week

June 13, 2018 - By Winifred Garcia

Harsco Corporation (NYSE:HSC) Logo

Among 5 analysts covering Harsco Corporation (NYSE:HSC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harsco Corporation had 14 analyst reports since August 17, 2015 according to SRatingsIntel. Jefferies maintained the shares of HSC in report on Thursday, August 3 with “Buy” rating. KeyBanc Capital Markets maintained Harsco Corporation (NYSE:HSC) on Wednesday, October 7 with “Overweight” rating. The firm earned “Buy” rating on Wednesday, May 2 by Lake Street. Jefferies maintained it with “Buy” rating and $1800 target in Thursday, June 15 report. KeyBanc Capital Markets maintained it with “Overweight” rating and $25 target in Wednesday, February 28 report. KeyBanc Capital Markets maintained it with “Overweight” rating and $27 target in Thursday, May 3 report. Lake Street initiated the stock with “Buy” rating in Tuesday, September 13 report. The rating was upgraded by Argus Research on Friday, September 15 to “Buy”. The firm earned “Overweight” rating on Monday, August 17 by KeyBanc Capital Markets. As per Friday, November 10, the company rating was maintained by KeyBanc Capital Markets. See Harsco Corporation (NYSE:HSC) latest ratings:

03/05/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $25 New Target: $27 Maintain
02/05/2018 Broker: Lake Street Rating: Buy New Target: $30.0000 Maintain
28/02/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $23 New Target: $25 Maintain
23/02/2018 Broker: Alembic Rating: Buy

Greenleaf Trust decreased Gw Pharmaceuticals Plc Adr (GWPH) stake by 4.48% reported in 2018Q1 SEC filing. Greenleaf Trust sold 2,950 shares as Gw Pharmaceuticals Plc Adr (GWPH)’s stock rose 36.14%. The Greenleaf Trust holds 62,944 shares with $7.09 million value, down from 65,894 last quarter. Gw Pharmaceuticals Plc Adr now has $4.33 billion valuation. The stock decreased 1.06% or $1.65 during the last trading session, reaching $153.47. About 44,928 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 49.14% since June 13, 2017 and is uptrending. It has outperformed by 36.57% the S&P500. Some Historical GWPH News: ; 19/04/2018 – FDA Advisory Panel Backs GW Pharmaceuticals’ Proposed Drug for Epilepsy; 12/04/2018 – ICC Labs Enters Into Term Sheet for Export of Cannabidiol to Sundial in Canada; 12/04/2018 – GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol oral solution) at the; 19/04/2018 – GWPH, ZYNE: Panel votes 13 to 0 that $GWPH’s Epidiolex (cannabidiol) has a favorable risk/benefit profile. – ! $GWPH $ZYNE; 30/04/2018 – Projects will not be focusing on the cannabis plant’s psychoactive compound, known as tetrahydrocannabinol, or THC; 13/03/2018 – GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five; 24/04/2018 – Isodiol Intl Inc. Announces the Launch of 3 New Cannabidiol (CBD) Pdt Categories With Level Brands Inc; 17/04/2018 – GW PHARMA’S CANNABIDIOL DRUG GETS FAVORABLE FDA STAFF REVIEW; 12/04/2018 – GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol oral solution) at the 2018 American Academy of Neurology Annual Meeting; 19/04/2018 – Epilepsy Foundation Testifies Before FDA Advisory Committee in Support of Potential First-Ever Cannabidiol Drug to Treat Dravet

More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Seekingalpha.com which released: “GW Pharmaceuticals: Value Beyond Epidiolex?” on June 04, 2018, also Nasdaq.com with their article: “Better Marijuana Stock: GW Pharmaceuticals vs. Cara Therapeutics” published on June 10, 2018, Prnewswire.com published: “International Cannabis Legalization to Spur Global Medical and Recreational Sales” on June 13, 2018. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Fool.com and their article: “Better Marijuana Stock: Scotts Miracle-Gro vs. GW Pharmaceuticals” published on June 03, 2018 as well as Fool.com‘s news article titled: “3 Biotechs With Huge FDA Decisions in June” with publication date: May 31, 2018.

Greenleaf Trust increased Ishares Msci Eafe Etf (EFA) stake by 45,967 shares to 258,489 valued at $18.01 million in 2018Q1. It also upped Steelcase Inc (NYSE:SCS) stake by 29,558 shares and now owns 619,239 shares. Carnival Plc (NYSE:CUK) was raised too.

Analysts await GW Pharmaceuticals plc (NASDAQ:GWPH) to report earnings on August, 6. They expect $-2.39 earnings per share, down 15.46% or $0.32 from last year’s $-2.07 per share. After $-3.12 actual earnings per share reported by GW Pharmaceuticals plc for the previous quarter, Wall Street now forecasts -23.40% EPS growth.

Among 13 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. GW Pharmaceuticals had 30 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Monday, December 5 with “Buy”. Cantor Fitzgerald maintained GW Pharmaceuticals plc (NASDAQ:GWPH) on Tuesday, August 8 with “Buy” rating. The stock has “Buy” rating by Roth Capital on Monday, March 14. The rating was maintained by Bank of America on Tuesday, November 14 with “Buy”. The firm has “Outperform” rating given on Tuesday, February 6 by Leerink Swann. Morgan Stanley initiated GW Pharmaceuticals plc (NASDAQ:GWPH) on Thursday, August 13 with “Overweight” rating. On Thursday, August 3 the stock rating was maintained by Piper Jaffray with “Buy”. On Friday, September 29 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Buy” rating by Goldman Sachs given on Thursday, December 14. The firm has “Buy” rating given on Thursday, December 28 by Leerink Swann.

Investors sentiment decreased to 0.95 in Q1 2018. Its down 0.23, from 1.18 in 2017Q4. It turned negative, as 17 investors sold Harsco Corporation shares while 90 reduced holdings. 41 funds opened positions while 61 raised stakes. 65.98 million shares or 1.20% more from 65.20 million shares in 2017Q4 were reported. James Research reported 0.14% in Harsco Corporation (NYSE:HSC). 63,621 were reported by Menta Capital. 598 are held by Carroll Financial Associates. Pinebridge Invests Limited Partnership accumulated 14,882 shares. Greenwood Cap Assoc Lc reported 10,057 shares stake. Price T Rowe Assocs Inc Md invested in 73,628 shares or 0% of the stock. State Street has 2.08 million shares for 0% of their portfolio. Moreover, State Of New Jersey Common Pension Fund D has 0.08% invested in Harsco Corporation (NYSE:HSC) for 1.00M shares. Pnc Fincl Service Gru holds 0% of its portfolio in Harsco Corporation (NYSE:HSC) for 27,141 shares. New York-based State Teachers Retirement Sys has invested 0.01% in Harsco Corporation (NYSE:HSC). Pub Employees Retirement System Of Ohio stated it has 72,402 shares or 0.01% of all its holdings. Hsbc Public Ltd Liability Corp stated it has 0% in Harsco Corporation (NYSE:HSC). Moreover, Smithfield Trust has 0% invested in Harsco Corporation (NYSE:HSC) for 200 shares. Whittier Trust has 2,622 shares. Huber Management Ltd Llc holds 547,527 shares.

More recent Harsco Corporation (NYSE:HSC) news were published by: Seekingalpha.com which released: “Harsco Back On Offense” on June 11, 2018. Also Globenewswire.com published the news titled: “Harsco Acquires ALTEK, a Leading Supplier of Innovative Environmental and Technology Products to the Global …” on May 29, 2018. Globenewswire.com‘s news article titled: “Harsco to Participate in 2018 KeyBanc Industrials & Basic Materials Conference” with publication date: May 25, 2018 was also an interesting one.

Harsco Corporation provides industrial services and engineered products worldwide. The company has market cap of $2.06 billion. The firm operates through three divisions: Harsco Metals & Minerals, Harsco Industrial, and Harsco Rail. It has a 277.72 P/E ratio. The Harsco Metals & Minerals segment provides on-site services of material logistics, product quality improvement, and resource recovery for iron, steel, and metals manufacturing; and value added environmental solutions for industrial co-products, as well as makes industrial abrasives and roofing granules.

The stock decreased 0.78% or $0.2 during the last trading session, reaching $25.55. About 9,457 shares traded. Harsco Corporation (NYSE:HSC) has risen 62.20% since June 13, 2017 and is uptrending. It has outperformed by 49.63% the S&P500. Some Historical HSC News: ; 25/04/2018 – Harsco Shareholders Elect Eight Director Nominees to Board; 02/05/2018 – Harsco Corp Announces $75 M Shr Repurchase Authorization; 29/05/2018 – HARSCO CORP – DEAL FOR £45 MLN; 25/04/2018 – Harsco Ratifies Audit Committee’s Appointment of PricewaterhouseCoopers LLP as Independent Auditors; 23/03/2018 – Fitch Affirms Harsco Corporation’s IDR at ‘BB’; Outlook Stable; 29/05/2018 – Harsco: Altek Acquistion Has Contingent Consideration Subject to Future Fincl Performance of Altek; 29/05/2018 – HARSCO BUYS ALTEK FOR £45M; 02/05/2018 – Harsco: 2018 GAAP and Adjusted Operating Income Expected to Range From $165 Million to $180 Million; 29/05/2018 – HARSCO CORP – ACQUIRED ALTEK, ON A DEBT AND CASH FREE BASIS; 02/05/2018 – Harsco 1Q Rev $408M

Harsco Corporation (NYSE:HSC) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>